Ping Du, MD, PhD

Articles

February 12th 2020

Discontinuation of New Hepatitis C Drugs Among Medicare Patients

Jeah Jung, PhD, MPH Ping Du, MD, PhD Roger Feldman, PhD Thomas Riley III, MD

Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

May 3rd 2016

Coverage for Hepatitis C Drugs in Medicare Part D

Jeah Kyoungrae Jung, PhD Roger Feldman, PhD Chelim Cheong, PhD Ping Du, MD, PhD Douglas Leslie, PhD

This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 1st 2024 | Updated: November 21st 2024

Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions